Literature DB >> 15577538

Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.

Angelos E Hatzakis1, Giota Touloumi, Nikos Pantazis, Cleo G Anastassopoulou, Olga Katsarou, Anastasia Karafoulidou, James J Goedert, Leondios G Kostrikis.   

Abstract

OBJECTIVE: To assess whether cellular HIV-1 DNA prior to highly active antiretroviral therapy (HAART) initiation predicts its outcome. DESIGN AND METHODS: Patients included all 51 hemophiliacs of the Greek component of the Multicenter Hemophilia Cohort Study who had initiated HAART and for whom cryopreserved lymphocyte samples before HAART initiation were available. Cellular HIV-1 DNA quantification was performed by a molecular beacon-based real-time PCR assay in multiple samples per patient with a median (interquartile range) follow-up of 76 (45-102) weeks.
RESULTS: The median (range) baseline HIV-1 DNA load was 297 (< 10 to 3468) copies per 1 x 10(6) peripheral blood mononuclear cells. Baseline HIV-1 DNA load did not predict initial virological response (VR). None of the patients with initial VR and baseline HIV-1 DNA load at or below the median experienced a subsequent virological rebound, while the cumulative probability of virological rebound by week 104 was 55% among those with HIV-1 DNA load greater than the median (P < 0.008). Cellular HIV-1 DNA load was the only parameter associated with sustained virological response as shown by univariate or multivariate analyses [adjusted odds ratio (95% confidence interval) 0.197 (0.048-0.801) per 1 log10 increase in DNA copies, P = 0.023].
CONCLUSION: Low cellular HIV-1 DNA load is a marker of sustained virological response in patients with initial VR and it can reliably predict the long-term success of HAART.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577538     DOI: 10.1097/00002030-200411190-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  16 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy.

Authors:  Saverio Giuseppe Parisi; Samantha Andreis; Carlo Mengoli; Renzo Scaggiante; Roberto Ferretto; Vinicio Manfrin; Mario Cruciani; Mario Giobbia; Caterina Boldrin; Monica Basso; Massimo Andreoni; Giorgio Palù; Loredana Sarmati
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

3.  In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment.

Authors:  Cari F Kessing; Christopher C Nixon; Chuan Li; Perry Tsai; Hiroshi Takata; Guillaume Mousseau; Phong T Ho; Jenna B Honeycutt; Mohammad Fallahi; Lydie Trautmann; J Victor Garcia; Susana T Valente
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

4.  Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV.

Authors:  Jérôme Legoff; Hicham Bouhlal; Gérard Grésenguet; Helen Weiss; Nzambi Khonde; Hakim Hocini; Nathalie Désiré; Ali Si-Mohamed; Jean de Dieu Longo; Cécile Chemin; Eric Frost; Jacques Pépin; Jean-Elie Malkin; Philippe Mayaud; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

5.  Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe.

Authors:  Victoria L Demetriou; David A M C van de Vijver; Ioanna Kousiappa; Claudia Balotta; Bonaventura Clotet; Zehava Grossman; Louise B Jørgensen; Snjezana Z Lepej; Itzchak Levy; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Francois Roman; Lidia Ruiz; Jean-Claude Schmidt; Anne-Mieke Vandamme; Kristel Van Laethem; Jurgen Vercauteren; Leondios G Kostrikis
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

6.  Development and assessment of a multiplex real-time PCR assay for quantification of human immunodeficiency virus type 1 DNA.

Authors:  A Beloukas; D Paraskevis; C Haida; V Sypsa; A Hatzakis
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

7.  Epigenetic Suppression of HIV in Myeloid Cells by the BRD4-Selective Small Molecule Modulator ZL0580.

Authors:  Edrous Alamer; Chaojie Zhong; Zhiqing Liu; Qingli Niu; Fuquan Long; Lulu Guo; Benjamin B Gelman; Lynn Soong; Jia Zhou; Haitao Hu
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

8.  Different patterns of HIV-1 DNA after therapy discontinuation.

Authors:  Maria Carla Re; Francesca Vitone; Laura Sighinolfi; Pasqua Schiavone; Florio Ghinelli; Davide Gibellini
Journal:  BMC Infect Dis       Date:  2005-09-12       Impact factor: 3.090

9.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.

Authors:  Sidonie Lambert-Niclot; Philippe Flandre; Marc-Antoine Valantin; Cathia Soulie; Slim Fourati; Marc Wirden; Sophie Sayon; Sophie Pakianather; Laurence Bocket; Bernard Masquelier; Georges Dos Santos; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.